Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population.
Fan YangXiang HuangChunxiao SunJianbin LiBiyun WangMin YanFeng JinHaibo WangJin ZhangPeifen FuTianyu ZengJian WangWei LiYongfei LiMengzhu YangJun LiHao WuZiyi FuYongmei YinZefei JiangPublished in: BMC cancer (2020)
The combination of lapatinib and capecitabine showed a prolonged PFS relative to TBP in patients who had progressed on trastuzumab.